"Comparative evaluation of immunogenicity of bivalent oral poliovirus vaccine (bOPV) and monovalent oral poliovirus vaccine type 1 (mOPV1) when administered in the EPI schedule with a dose of inactivated polio vaccine (IPV) at week 14 and assessment of immunogenicity of IPV only schedule in the EPI: A multicentric open label randomized controlled trial" - WHO mOPV1 study

Trial Profile

"Comparative evaluation of immunogenicity of bivalent oral poliovirus vaccine (bOPV) and monovalent oral poliovirus vaccine type 1 (mOPV1) when administered in the EPI schedule with a dose of inactivated polio vaccine (IPV) at week 14 and assessment of immunogenicity of IPV only schedule in the EPI: A multicentric open label randomized controlled trial" - WHO mOPV1 study

Not yet recruiting
Phase of Trial: Phase IV

Latest Information Update: 08 Sep 2016

At a glance

  • Drugs Poliovirus vaccine inactivated (Primary) ; Poliovirus vaccine live oral (Primary) ; Poliovirus vaccine
  • Indications Poliomyelitis
  • Focus Pharmacodynamics
  • Sponsors Panacea Biotec
  • Most Recent Events

    • 08 Sep 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top